Abstract
Surufatinib (S, a small-molecule inhibitor of VEGFR1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) has exhibited encouraging efficacy in an SCLC cohort in a trial evaluating S + T in pts with selected solid tumors. This study is assessing the safety, tolerability, and preliminary efficacy of S+ T+ chemotherapy (EP) as first-line regimen for SCLC pts. Here, we report the preliminary efficacy results.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
